
## Michael B Nichol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9570092/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases. Value in Health, 2007, 10, 3-12.	0.3	534
2	Patientâ€reported reasons for discontinuing overactive bladder medication. BJU International, 2010, 105, 1276-1282.	2.5	336
3	Medication Adherence and Associated Hemoglobin A1c in Type 2 Diabetes. Annals of Pharmacotherapy, 2004, 38, 1357-1362.	1.9	248
4	Persistence and Adherence of Medications for Chronic Overactive Bladder/Urinary Incontinence in the California Medicaid Program. Value in Health, 2005, 8, 495-505.	0.3	171
5	The Costs of Interrupting Antihypertensive Drug Therapy in a Medicaid Population. Medical Care, 1994, 32, 214-226.	2.4	169
6	Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer. Value in Health, 2009, 12, 124-129.	0.3	163
7	A Critical Evaluation of the Methodology of the Literature on Medication Compliance. Annals of Pharmacotherapy, 1999, 33, 531-540.	1.9	102
8	Compliance with Sulfonylureas in a Health Maintenance Organization: A Pharmacy Record–Based Study. Annals of Pharmacotherapy, 1999, 33, 281-288.	1.9	95
9	Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. Journal of Medical Economics, 2015, 18, 457-465.	2.1	87
10	The Clinical and Economic Burden of Nonadherence with Antihypertensive and Lipid-Lowering Therapy in Hypertensive Patients. Value in Health, 2009, 12, 489-497.	0.3	70
11	Evaluating Use Patterns of and Adherence to Medications for Benign Prostatic Hyperplasia. Journal of Urology, 2009, 181, 2214-2222.	0.4	58
12	Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vascular Health and Risk Management, 2008, 4, 673-81.	2.3	54
13	Quality of Anticoagulation Monitoring in Nonvalvular Atrial Fibrillation Patients: Comparison of Anticoagulation Clinic versus Usual Care. Annals of Pharmacotherapy, 2008, 42, 62-70.	1.9	48
14	The Impact of Value-Based Benefit Design on Adherence to Diabetes Medications: A Propensity Score-Weighted Difference in Difference Evaluation. Value in Health, 2010, 13, 846-852.	0.3	47
15	Mapping the SF-12 to the HUI3 and VAS in a Managed Care Population. Medical Care, 2004, 42, 927-937.	2.4	45
16	Multiple Medication Adherence and its Effect on Clinical Outcomes Among Patients With Comorbid Type 2 Diabetes and Hypertension. Medical Care, 2013, 51, 879-887.	2.4	44
17	Cost of care for early―and lateâ€stage oral and pharyngeal cancer in the California Medicaid population. Head and Neck, 2008, 30, 178-186.	2.0	43
18	Medication Use in Residential Care Facilities for the Elderly. Annals of Pharmacotherapy, 1999, 33, 149-155.	1.9	42

#	Article	IF	CITATIONS
19	Costâ€effectiveness of Prostate Health Index for prostate cancer detection. BJU International, 2012, 110, 353-362.	2.5	41
20	Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status. American Journal of Hematology, 2015, 90, S11-6.	4.1	41
21	Estimating the Effect of Medication Adherence on Health Outcomes among Patients with Type 2 Diabetes—An Application of Marginal Structural Models. Value in Health, 2010, 13, 1038-1045.	0.3	38
22	The demand for statin: the effect of copay on utilization and compliance. Health Economics (United) Tj ETQq0 (	) 0 rgBT /C E7	Overlock 10 Tf
23	A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clinical Therapeutics, 2009, 31, 421-435.	2.5	33
24	Antipsychotic Drug Use Patterns and the Cost of Treating Schizophrenia. Psychiatric Services, 2000, 51, 525-527.	2.0	32
25	Racial/ethnic differences in the use of biologic diseaseâ€modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care and Research, 2013, 65, 299-303.	3.4	32
26	The Kaiser Permanente/USC Patient Consultation Study: Change in use and cost of health care services. American Journal of Health-System Pharmacy, 1998, 55, 2485-2499.	1.0	31
27	The Effects of Consultation on Over-the-Counter Medication Purchasing Decisions. Medical Care, 1992, 30, 989-1003.	2.4	30
28	Transitioning the Second-Generation Antihistamines to Over-the-Counter Status. Medical Care, 2003, 41, 1382-1395.	2.4	30
29	The Impact of Change in Visual Field on Health-Related Quality of Life. Ophthalmology, 2011, 118, 1310-1317.	5.2	29
30	Budget impact analysis of a new prostate cancer risk index for prostate cancer detection. Prostate Cancer and Prostatic Diseases, 2011, 14, 253-261.	3.9	29
31	Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates. Value in Health, 2017, 20, 1074-1082.	0.3	29
32	The Role of SSRI Antidepressants for Treating Depressed Patients in the California Medicaid (Medi-Cal) Program. Value in Health, 1999, 2, 269-280.	0.3	24
33	Measuring the Effects of Medication Use on Health-Related Quality of Life in Patients with Rheumatoid Arthritis. Pharmacoeconomics, 1999, 16, 433-448.	3.3	24
34	Physical activity and health outcomes in persons with haemophilia B. Haemophilia, 2014, 20, 814-821.	2.1	24
35	Nonadherence to clinical practice guidelines and medications for multiple chronic conditions in a California Medicaid population. Journal of the American Pharmacists Association: JAPhA, 2010, 50, 496-507.	1.5	22
36	Changes in serum prostateâ€specific antigen levels and the identification of prostate cancer in a large managed care population. BJU International, 2013, 111, 1245-1252.	2.5	22

MICHAEL B NICHOL

#	Article	IF	CITATIONS
37	Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence. Clinical Therapeutics, 2008, 30, 761-774.	2.5	21
38	Transition Probabilities and Predictors of Adherence in a California Medicaid Population Using Antihypertensive and Lipid-Lowering Medications. Value in Health, 2009, 12, 544-550.	0.3	21
39	The Increased Cost of Medical Services for People Diagnosed With Primary Open-Angle Glaucoma: A Decision Analytic Approach. American Journal of Ophthalmology, 2010, 150, 74-81.	3.3	21
40	Utilization Patterns of Antidepressant Medications in a Patient Population Served by a Primary Care Medical Group. Journal of Managed Care Pharmacy, 1999, 5, 243-249.	2.2	20
41	Generic and therapeutic statin switches and disruptions in therapy. Current Medical Research and Opinion, 2009, 25, 1247-1260.	1.9	20
42	Pharmacy-Enforced Outpatient Drug Treatment Protocols: A Case Study of Medi-Cal Restrictions for Cefaclor. Annals of Pharmacotherapy, 1993, 27, 155-161.	1.9	19
43	Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser permanente/USC patient consultation study. Clinical Therapeutics, 1995, 17, 1188-1206.	2.5	19
44	Longitudinal Changes in Health-Related Quality of Life for Chronic Diseases: An Example in Hemophilia A. Journal of General Internal Medicine, 2014, 29, 760-766.	2.6	18
45	Eligibility, utilization, and costs in a California Medicaid lupus population. Arthritis and Rheumatism, 2004, 51, 996-1003.	6.7	17
46	Public Members on Occupational Licensing Boards: Effects on Legislative Regulatory Reforms. Southern Economic Journal, 1989, 55, 610.	2.1	16
47	Depression and health-related quality of life in patients with rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 645-653.	1.4	16
48	Nonâ€severe haemophilia: Is it benign? – Insights from the PROBE study. Haemophilia, 2021, 27, 17-24.	2.1	16
49	Cost-Benefit Analysis of First-Generation Antihistamines in the Treatment of Allergic Rhinitis. Pharmacoeconomics, 2004, 22, 929-942.	3.3	15
50	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open, 2018, 8, e021900.	1.9	15
51	Consumer Knowledge of Over-the-Counter Phenazopyridine. Annals of Family Medicine, 2004, 2, 240-244.	1.9	14
52	The Economic Impact of Payer Policies after the Rx-to-OTC Switch of Second-Generation Antihistamines* *Preliminary results of this analysis were presented at the 9th annual HMO Research Network Conference April 1-2, 2003. Value in Health, 2004, 7, 402-412.	0.3	14
53	Inside the Black Box: The Case Review Process of an Elder Abuse Forensic Center. Gerontologist, The, 2016, 56, 772-781.	3.9	14
54	Testâ€retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia, 2019, 25, 75-83.	2.1	14

MICHAEL B NICHOL

#	Article	IF	CITATIONS
55	Usage patterns of over-the-counter phenazopyridine (pyridium). Journal of General Internal Medicine, 2003, 18, 281-287.	2.6	13
56	Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and without Cardiovascular Risk. Value in Health, 2006, 9, 361-368.	0.3	13
57	Opinions Regarding the Academy of Managed Care Pharmacy Dossier Submission Guidelines: Results of a Small Survey of Managed Care Organizations and Pharmaceutical Manufacturers. Journal of Managed Care Pharmacy, 2007, 13, 360-371.	2.2	13
58	Separating gains and losses in health when calculating the minimum important difference for mapped utility measures. Quality of Life Research, 2008, 17, 955-961.	3.1	13
59	Prevalence and incidence of adult attention deficit/hyperactivity disorder in a large managed care population. Current Medical Research and Opinion, 2014, 30, 1291-1299.	1.9	13
60	Critical Analysis of the Content and Enforcement of Mandatory Consultation and Patient Profile Laws. Annals of Pharmacotherapy, 1992, 26, 1149-1155.	1.9	11
61	Exploring regional variations in the crossâ€cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. Haemophilia, 2019, 25, 365-372.	2.1	11
62	Structural Reforms and Licensing Board Performance. American Politics Research, 1990, 18, 376-400.	0.7	9
63	Impact of Mental Health Comorbidities on Health Care Utilization and Expenditure in a Large US Managed Care Adult Population with ADHD. Value in Health, 2014, 17, 661-668.	0.3	9
64	An economic analysis of antimicrobial prophylaxis against urinary tract infection in patients undergoing transurethral resection of the prostate. Clinical Therapeutics, 1999, 21, 1589-1603.	2.5	8
65	Is pharmacy's vision of the future too narrow?. American Journal of Health-System Pharmacy, 1995, 52, 1208-1214.	1.0	7
66	The Impact of an Over-the-Counter Migraine Medication Program on Quality of Life. Headache, 2003, 43, 191-201.	3.9	7
67	The Use of First- and Second-Line Outpatient Antibiotics Under the Saskatchewan Drug Plan. Pharmacoeconomics, 1995, 7, 543-554.	3.3	5
68	PSY11 ESTIMATION OF CAUSAL EFFECTS OF PHYSICAL ACTIVITY ON OBESITY BY A RECURSIVE BIVARIATE PROBIT MODEL. Value in Health, 2009, 12, A131-A132.	0.3	5
69	INCREMENTAL EXPENDITURE OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC TREATMENT USING INSTRUMENTAL VARIABLES IN PANEL DATA. Health Economics (United Kingdom), 2013, 22, 807-823.	1.7	4
70	AD4: A TIME-VARYING SURVIVAL MODEL FOR THE ASSOCIATION OF ADHERENCE WITH HMG-COA INHIBITORS TO THE RISK OF ADVERSE EVENTS. Value in Health, 2003, 6, 191-192.	0.3	2
71	The Role of Outcomes Research in Defining and Measuring Value in Benefit Decision. Journal of Managed Care Pharmacy, 2006, 12, S19-S23.	2.2	2
72	Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia—Hematology Utilization Group Study Part VII (HUGS VII). Journal of Blood Medicine, 2022, Volume 13, 229-241.	1.7	2

#	Article	IF	CITATIONS
73	Adalimumab for Rheumatoid Arthritis. Disease Management and Health Outcomes, 2004, 12, 1-8.	0.4	1
74	Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model. Health Services and Outcomes Research Methodology, 2018, 18, 75-95.	1.8	0